Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: caspase inhibitors - New World Laboratories

Next Previous
Drug Profile

Research programme: caspase inhibitors - New World Laboratories

Alternative Names: NWL 149; NWL 154; NWL 53

Latest Information Update: 22 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New World Laboratories
  • Class Anti-inflammatories; Antidementias; Antineoplastics; Antiparkinsonians; Peptidomimetics; Vascular disorder therapies
  • Mechanism of Action Caspase 1 inhibitors; Caspase 3 inhibitors; Caspase 4 inhibitors; Caspase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries; Cancer; Huntington's disease; Inflammation; Multiple sclerosis; Myocardial infarction; Parkinson's disease; Spinal cord injuries; Stroke

Most Recent Events

  • 22 Sep 2023 Preclinical development in Alzheimer's disease, Brain injuries, Cancer, Huntington's disease, Multiple sclerosis, Stroke, Spinal cord injuries, Parkinson's disease, Myocardial infarction and Inflammation is still ongoing in Canada (New World Laboratories pipeline, September 2023)
  • 28 Dec 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
  • 28 Dec 2020 No recent reports of development identified for preclinical development in Brain injuries in Canada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top